Short answer
Lantheus Holdings, Inc. (LNTH) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $388M (up 2.7% year over year) with net income of $75M.
Q2 2026 key financials · XBRL
- Revenue
- $388M
- +2.7% YoY · +2.9% QoQ
- Net income
- $75M
- −4.7% YoY · −36.6% QoQ
- Operating margin
- 25.8%
- Gross margin
- 62.3%
- EPS (diluted)
- $1.11
- −0.9% YoY · −38.3% QoQ
Source: XBRL data from the Lantheus Holdings, Inc. (LNTH) Q2 2026 10-Q on SEC EDGAR. USD.
Lantheus Holdings, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Pending Curium merger triggered new closing risk, including shareholder approval and HSR antitrust clearance requirements
- Most material merger risk: $228.0 million termination fee, potentially reducing cash available for corporate purposes
- Regulatory risk: FDA Complete Response Letter for LNTH-2501 citing unresolved third-party manufacturing conditions
- Operational risk: PYLARIFY TruVu rollout begins fourth quarter 2026, requiring PMF approvals and customer transitions
- Financial risk: unsecured $20.0 million Seller Note and $25.0 million deferred cash consideration depend on SHINE SPECT payment capacity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lantheus Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.